EGFR and non-small cell lung carcinoma: Our studies are in accordance with previous studies, which showed that CNR2 agonists inhibit the tumor growth and metastasis through induction of apoptosis and inhibition of EGFR activation in non-small cell lung cancer (NSCLC) [5].